Key Cancer Drugs to Watch at ESMO 2025: Investor and BD Insights

Key Cancer Drugs to Watch at ESMO 2025: Investor and BD Insights

ESMO 2025 is expected to unveil critical data on next-generation cancer therapies. This article highlights key drugs and their implications for pharmaceutical business development, investment strategies, and the evolving oncology landscape. For BD teams and analysts tracking catalysts, the July and September congresses will deliver practice-changing readouts across breast, prostate, and lung cancers that could reshape partnership decisions and market access strategies.

Key Takeaways

• Precision medicine emerged as the dominant theme at ESMO 2025, demanding that pharma and biotech translate complex biomarker science into actionable testing and access strategies to drive patient outcomes.
• Updated overall survival data from the MonarchE trial — showing 301 deaths in the abemaciclib plus endocrine therapy arm versus 360 in the control arm at 6.3 years of follow-up — will inform competitive positioning in high-risk early breast cancer and influence label expansion discussions with regulators.
• Immunotherapy continues its march into earlier treatment settings and new tumor types, with data from the ESMO TAT Asia Congress and the main ESMO Congress expected to affect deal flow in bispecifics, ADCs, and radiopharmaceuticals.
• Oncology drug shortages remain a persistent headwind, and companies that demonstrate strong supply chain strategies may gain advantage in payer negotiations and formulary placement as new therapies launch.

ESMO 2025: A Crucial Forum for Oncology Data

The 2025 European Society for Medical Oncology calendar kicked off with the ESMO TAT Asia Congress, held 18–20 July 2025 in Hong Kong SAR, China. The event convened researchers, clinicians, regulators, and industry leaders to discuss early-phase trial design, biomarker-driven development, and the regulatory path for targeted therapies in the Asia-Pacific region. The main ESMO Congress, scheduled for September 2025 in Madrid, will serve as the year’s flagship venue for late-breaking abstracts across all major tumor types. Together, these meetings represent critical catalyst events for biotech stocks and BD pipelines, with practice-changing data expected in prostate, breast, and lung cancers.

Key Cancer Drugs and Data to Watch

The most closely watched breast cancer dataset at ESMO 2025 came from the MonarchE trial, evaluating abemaciclib plus endocrine therapy in high-risk early breast cancer. Updated results presented at the congress delivered the primary overall survival analysis, a secondary endpoint, alongside updated invasive disease-free survival and distant recurrence-free survival figures. In the intention-to-treat population, with a median follow-up of 6.3 years, 301 patients in the abemaciclib plus endocrine therapy arm had died versus 360 in the endocrine therapy-alone arm (ClinicalTrials.gov). These data are pivotal for Lilly’s competitive positioning against other CDK4/6 inhibitors and will inform FDA and EMA label discussions around adjuvant treatment duration and patient selection.

Another high-profile readout comes from the DESTINY-Breast11 Phase III study, evaluating Enhertu followed by paclitaxel, trastuzumab, and pertuzumab in the neoadjuvant setting. Positive data could expand the ADC’s reach into earlier-stage HER2-positive breast cancer, intensifying the competition with trastuzumab-based regimens and potentially reshaping surgical outcomes.

Beyond breast cancer, ESMO 2025 is expected to feature breakthroughs in prostate, ovarian, and bladder cancer. Novartis’s Pluvicto in prostate cancer and Merck & Co.’s candidates in platinum-resistant ovarian cancer are among the programs that could shift treatment algorithms. Immunotherapy is pushing into new tumor types, earlier lines, and novel combination regimens, a theme that will drive licensing interest in bispecifics and next-generation checkpoint inhibitors.

Implications for Pharma Business Development and Regulatory Teams

The data cascade from ESMO 2025 demands coordinated action from BD and regulatory teams. For business development, the MonarchE OS readout and DESTINY-Breast11 results will be benchmarked against existing standard-of-care regimens, helping BD teams identify assets that offer differentiation in efficacy, safety, or biomarker-defined subpopulations. Licensing, co-development, and acquisition targets in the ADC and radiopharmaceutical spaces are likely to attract heightened attention as late-stage data clarify commercial viability.

Regulatory teams must prepare for potential label expansions and new drug applications triggered by ESMO data. The FDA and EMA will scrutinize overall survival benefits, especially in adjuvant settings where surrogate endpoints like invasive disease-free survival are commonly used for accelerated approval. Companies should align their regulatory strategies with emerging guidelines and anticipate requests for real-world evidence to support post-marketing commitments. In parallel, the persistent issue of oncology drug shortages, identified in 15 drugs between 2023 and 2025 using the FDA’s Drug Shortage Database (PMC), means that supply chain resilience will factor into both regulatory reviews and market access negotiations.

Market access teams will need to build value dossiers that incorporate ESMO data, emphasizing not just efficacy but also addressing barriers to testing, biomarker adoption, and treatment affordability. As precision medicine becomes central to oncology strategy, companies that invest in companion diagnostics and patient identification programs will be better positioned to capture market share.

Frequently Asked Questions

Related coverage

• Hayes Receives 2026 ESMO Breast Cancer Award: Key Insights
• Florian Lordick Elected ESMO President 2029–2030: What Pharma Teams Should Watch
• Insights from ESMO Asia: Nadia Harbeck on Oncology Advances